This position paper outlines considerations for the complex anticoagulant management of cancer patients who present with both chronic kidney disease and venous thromboembolism.
Answers are grounded in this paper and cite their sources.
Position paper on CKD-thrombosis-cancer links; leaves open need for prospective data before practice change.
Cancer & the Kidney International Network was created in 2014. The aim was to improve the management of cancer patients by developing clinical and scientific knowledge on the main topic of cancer and the kidney. Therefore, the Cancer & the Kidney International Network created a special working group: the Thrombosis, Kidney Disease, and Cancer working Group. The first step of this force was to produce a position paper on this topic by investigating the association of chronic kidney disease and venous thromboembolism in cancer patients, focusing particularly on the anticoagulant management of patients presenting these three comorbidities. The use of low-molecular-weight heparins, vitamin K agonists and oral direct anticoagulants in cancer patients with chronic kidney disease was reviewed.
No takes yet. Share an insight, caveat, or question.
Launay‐Vacher et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: